Englander Institute for Precision Medicine
Photo credit: EIPM

June 2022 EIPM Director's Memo

June 6, 2022

Dear Members of the Englander Institute,

I really enjoy talking to people about the exciting work happening at the EIPM, it can lead to all kinds of collaborations, professional opportunities, and new sources of support.

That’s one of the reasons I was happy to invite Charlie Roberts, co-founder and Chief Growth Officer of Freenome, to visit recently with our staff and tour our labs. Because VIPs & ...

Read More
Photo credit: Shutterstock

Immune Therapy Targets Cells that Cause Relapse

June 3, 2022

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine. The new cell therapy, now being tested in phase 1 clinical trials, may ultimately help patients with AML to remain cancer-free.

In the ...

Read More
Dr. Ekta Khurana

New Cancer Subtype May Illuminate Treatment Strategy

May 27, 2022

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.

In the study, published May 27 in Science, the researchers...

Read More